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ABSTRACT
A surveillance study was performed throughout Germany from November 2001 to June 2002 to assess
the prevalence of linezolid-resistant isolates among Gram-positive bacteria from routine susceptibility
data and to compare the in-vitro activity of linezolid to that of other antibacterial agents. Each of 86
laboratories provided routine susceptibility data for 100 consecutive isolates. Most laboratories (c. 60%)
used the disk diffusion test. Laboratories were also requested to send a representative sample of their
isolates, as well as all isolates reported as intermediate or resistant to linezolid, to a reference laboratory
for MIC determination. Susceptibility data for 8594 isolates were evaluated. Sites of infection were skin
and soft tissue (29.9%), upper and lower respiratory tract (19.1%), foreign body or catheter (10.5%), or
urinary tract (9.8%). Routine linezolid susceptibility data were reported for 6433 isolates. The prevalence
of linezolid resistance, as reported to the clinician, was 0.4% in Staphylococcus aureus, 0.3% in
Staphylococcus epidermidis, 2.9% in Enterococcus faecalis, 2.3% in Enterococcus faecium, 1.4% in Streptococcus
pyogenes and 2.9% in Streptococcus agalactiae. Linezolid resistance was not detected in Streptococcus
pneumoniae or in viridans group streptococci. Sixty-nine of 115 isolates reported as intermediate or
resistant to linezolid were retested, but none was resistant to linezolid. Linezolid exhibited excellent
in-vitro activity against representative isolates of the six most frequently encountered species (MIC90,
1–2 mg ⁄L). The prevalence of resistance to linezolid was very low in Germany. Organisms reported as
linezolid-resistant should be retested, either in the same laboratory with an alternative method or in a
reference laboratory.
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INTRODUCTION
The growing resistance to many antibiotics in
Gram-positive pathogens, and the spread of
resistant organisms in both the community and
the hospital setting, means that antimicrobial
therapy is becoming increasingly complicated.
Therefore, a real need exists for new treatment
options for Gram-positive infections, and for a
reduction in the increasing selection pressure
caused by the antibacterial agents being used
currently [1–5].
Linezolid is the ﬁrst representative of a new
class of systemic antibacterial agents, the oxazo-
lidinones, which have a unique mode of action
whereby assembly of a functional initiation com-
plex for bacterial protein biosynthesis is blocked
[6]. As this mode of action differs from those of
other protein synthesis inhibitors, linezolid shows
no cross-resistance to other classes of antimicro-
bial agent with the same target [7]. Linezolid
exhibits an antibacterial spectrum that includes all
frequently encountered Gram-positive species,
including multiresistant strains [8–13], and has
shown considerable promise in the treatment of
Gram-positive infections in phase III studies [14].
Linezolid was approved in 2001 by regulatory
authorities in Europe and the USA. Shortly after
the introduction of linezolid in Germany, a
surveillance study was started by a network of
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clinical microbiology laboratories throughout
Germany to assess the prevalence of linezolid
resistance. Routine susceptibility testing results
generated by the participating laboratories were
requested, and the in-vitro activity of linezolid
was compared to that of other antibacterial agents
against a representative sample of isolates with a
standardised method in a reference laboratory.
METHODS AND MATERIALS
Eighty-six laboratories participated in the study. Laboratories
were either afﬁliated to university hospitals (n = 30), teaching
hospitals (n = 22) or public health institutions (n = 2), or were
private diagnostic laboratories (n = 32). Each laboratory was
requested to collect and test 100 consecutive clinically
signiﬁcant Gram-positive isolates (one isolate ⁄patient), com-
prising 35 Staphylococcus aureus, 30 coagulase-negative
staphylococci (CNS) (blood culture isolates only), 20 entero-
cocci (15 Enterococcus faecalis and ﬁve Enterococcus faecium),
ﬁve Streptococcus pneumoniae, ﬁve Streptococcus pyogenes and
ﬁve viridans group streptococci from hospitalised patients
during an 8-month period. A case report form was completed
for each isolate, giving the patient’s age and gender, site and
type of infection, type of specimen, the routine susceptibil-
ity testing method used and the susceptibility results
obtained.
Methods for identiﬁcation of bacteria and susceptibility
testing (i.e., agar diffusion, broth microdilution or an automa-
ted system) were those performed routinely. Susceptibility
results for antibacterial agents considered to be important for
the treatment of Gram-positive infections (according to the
investigator’s opinion) were recorded. All participating labor-
atories were accredited by an annual quality assurance
programme (http://www.instand-ev.de).
Laboratories were requested to send a representative
sample of their isolates, as well as all isolates reported to the
clinician as non-susceptible, i.e., reduced susceptibility to
linezolid in routine susceptibility tests, deﬁned as an MIC
‡ 4 mg ⁄L or an inhibition zone diameter £ 22 mm (enterococci)
or £ 20 mm (staphylococci, streptococci and pneumococci),
respectively, to a reference laboratory (Antiinfectives Intelli-
gence, Bonn, Germany) for retesting and conﬁrmation.
The subset of representative isolates (every tenth con-
secutive isolate) was tested in the reference laboratory
against linezolid in comparison to 11 other antimicrobial
agents with the broth microdilution method according to
German (DIN) guidelines [15]. Microdilution trays contain-
ing vacuum-dried antibacterial agents were purchased from
Merlin Diagnostika (Bornheim-Hersel, Germany). The quality
control strains used were Strep. pneumoniae ATCC 49619,
Staph. aureus ATCC 25923 and ATCC 29213, and E. faecalis
ATCC 29212.
Breakpoints (S £ ⁄R >, in mg ⁄L) for penicillin G (0.125 ⁄ 1 for
pneumococci and streptococci, 0.125 ⁄ 0.125 for staphylococci),
ampicillin (2 ⁄ 8), oxacillin (1 ⁄ 1), clindamycin (1 ⁄ 4), erythromy-
cin (1 ⁄ 4), doxycycline (1 ⁄ 4) and vancomycin (4 ⁄ 8) were those
recommended by DIN [16]. NCCLS breakpoints (S £ ⁄R ‡, in
mg ⁄L) [17,18] were used for levoﬂoxacin (2 ⁄ 8), rifampicin
(1 ⁄ 4) and quinupristin–dalfopristin (1 ⁄ 4). Breakpoints for
teicoplanin were those recommended by DIN for vancomycin
(S £ 4 ⁄R > 8). Breakpoints for linezolid were those recommen-
ded by the manufacturer (Pharmacia GmbH, Erlangen, Ger-
many) and stated in the Summary of Product Characteristics
(SmPC) approved by the European Agency for the Evaluation
of Medicinal Products, namely £ 2 mg ⁄L (S), 4 mg ⁄L (I) and
‡ 8 mg ⁄L (R).
RESULTS
Bacterial isolates
During the period November 2001 to June 2002,
the 86 participating laboratories provided suscep-
tibility testing results for 8594 Gram-positive
bacterial isolates, with an average number of 100
isolates ⁄ site (range 51–126). Staphylococci
(n = 5155) comprised 3844 (44.7%) Staph. aureus,
1040 CNS (773 Staph. epidermidis, 267 other spe-
cies) and 271 staphylococci with no species
identiﬁcation. Other organisms collected were
E. faecalis (n = 1188; 13.8%), E. faecium (n = 524;
6.1%), unidentiﬁed enterococci (n = 254; 2.6%),
Strep. pneumoniae (n = 480; 5.7%), Strep. pyogenes
(n = 392; 4.7%), Streptococcus agalactiae (n = 105;
1.2%), viridans group streptococci (n = 223;
2.6%), and isolates of various other Gram-positive
species (n = 273; 3.2%).
Patients and hospital wards
Bacteria were obtained from 4777 (55.6%) male
and 3665 (42.6%) female patients. The gender was
not speciﬁed for 152 patients (1.8%). The mean
ages of the male and female patients were 53.4
(± 23.5) and 54.9 (± 25.6) years, respectively. Most
(51.2%) isolates were obtained from patients on
general wards, followed by patients on intensive
care units (20.8%), paediatric wards (7.4%), hae-
mato-oncology wards (3.7%) and organ trans-
plantation wards (0.8%).
Sites of infection
The most frequent infections were complicated
and uncomplicated skin ⁄ skin structure infections
and post-operative wound infections (29.9%),
upper and lower respiratory tract infections
(19.1%), infections of unknown origin (18.5%),
foreign body ⁄ catheter infections (10.5%) and
urinary tract infections ⁄urosepsis (9.8%). Speci-
mens were recovered primarily from wounds
(29.4%), blood (23.4%), urine (9.6%) and the
lung ⁄ respiratory tract (8.0%).
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Prevalence of resistance based on routine
susceptibility data
Of the 8594 isolates, 6433 (74.9%) were tested
routinely against linezolid (Table 1), with c. 60%
of the susceptibility results provided as disk
diffusion data by the participating laboratories.
Susceptibility data for linezolid (and many other
antibiotics) were missing for 2161 isolates, as
participating laboratories routinely used different
panels of antibiotics. The prevalences of resistance
for the most important species–antibiotic combi-
nations were as follows.
Staphylococci
Among 2848 Staph. aureus isolates, six (0.2%) were
reported as intermediately resistant and ten
(0.4%) as resistant to linezolid. Rates of penicillin
and oxacillin (methicillin) resistance were 77.6%
and 16.9%, respectively. Five (0.3%) isolates were
reported as resistant to teicoplanin and four
(0.2%) as resistant to vancomycin. Among isolates
of CNS, two (0.3%) of 632 Staph. epidermidis and
one (0.6%) of 167 unidentiﬁed isolates were
reported as resistant to linezolid. The rate of
oxacillin resistance in Staph. epidermidis was
57.0%, while that for glycopeptides was < 1%
(vancomycin, 0.2%; teicoplanin, 0.9%).
Enterococci
Of the 853 E. faecalis and 400 E. faecium isolates,
25 (2.9%) and nine (2.3%), respectively, were
reported as resistant to linezolid. There were ﬁve
(2.4%) linezolid-resistant isolates among the 211
enterococcal isolates without species identiﬁca-
tion. Of the E. faecalis isolates, 2.6% were resistant
to ampicillin, 0.4% to vancomycin, and 0.5% to
teicoplanin. In contrast, the rates of resistance in
E. faecium were 82.7% to ampicillin, 4.3% to
vancomycin, and 0.7% to teicoplanin. Resistance
to quinupristin–dalfopristin was reported in
11.6% of the E. faecium isolates.
Streptococci
All Strep. pneumoniae isolates (n = 346) were sus-
ceptible to linezolid. The frequency of penicillin-
non-susceptible pneumococci was 3.2% (2.6%
intermediate; 0.6% resistant). Resistance to eryth-
romycin and clindamycin was observed in 14.7%
and 6.4%, respectively, of the isolates tested. Four
(1.4%) of 279 Strep. pyogenes isolates, two (2.9%)
of 70 Strep. agalactiae isolates, and one (0.6%) of
161 isolates without species identiﬁcation were
resistant to linezolid, whereas all 173 viridans
group streptococcal isolates were susceptible to
linezolid. As expected, all isolates of Strep. pyo-
genes were penicillin-susceptible. The rates of
erythromycin and clindamycin resistance were
9.3% and 1.8%, respectively. Of the 70 Strep.
agalactiae isolates, 2.9% and 5.8%, respectively,
were reported as resistant to penicillin and eryth-
romycin.
Retesting of isolates in the reference laboratory
In total, 115 (1.8%) of 6433 isolates were reported
initially as intermediately resistant or resistant to
linezolid by the participating laboratories. Of
these isolates, 69 (24 Staph. aureus, 19 E. faecalis,
11 E. faecium, seven Enterococcus spp., three Staph.
epidermidis, three Strep. pyogenes and two Strep.
pneumoniae), collected by 62 laboratories, were
Table 1. Susceptibility of Gram-positive cocci (n = 6433)
to linezolid, based on routine susceptibility testing data
supplied by the participating laboratories
Organism N
Number of strains (%) reported as
S I R
n % n % n %
Staphylococci
Staphylococcus aureus 2848 2832 99.4 6 0.2 10 0.4
Staphylococcus epidermidis 632 630 99.7 0 0 2 0.3
Staphylococcus haemolyticus 73 73 100 0 0 0 0
Staphylococcus hominis 66 66 100 0 0 0 0
Other coagulase-negative speciesa 92 92 100 0 0 0 0
Staphylococcus spp.b 167 166 99.4 0 0 1 0.6
Enterococci
Enterococcus faecalis 853 801 93.9 27 3.2 25 2.9
Enterococcus faecium 400 375 93.8 16 4.0 9 2.3
Other speciesc 22 22 100 0 0 0 0
Enterococcus spp.b 211 199 94.3 7 3.3 5 2.4
Streptococci
Streptococcus pneumoniae 346 346 100 0 0 0 0
Streptococcus pyogenes 279 275 98.6 0 0 4 1.4
Streptococcus agalactiae 70 68 97.1 0 0 2 2.9
Viridans group streptococcid 173 173 100 0 0 0 0
Other speciese 40 40 100 0 0 0 0
Streptococcus spp.b 161 160 99.4 0 0 1 0.6
aComprising two Staphylococcus auricularis, 33 Staphylococcus capitis, two Staphylo-
coccus chromogenes, one Staphylococcus cohnii, one Staphylococcus gallinarum, one
Staphylococcus hyicus, one Staphylococcus intermedius, 13 Staphylococcus lugdunensis,
11 Staphylococcus saprophyticus, one Staphylococcus schleiferi, one Staphylococcus scuri,
eight Staphylococcus simulans, 15 Staphylococcus warneri and two Staphylococcus
xylosus.
bIsolates without species identiﬁcation by the routine laboratory.
cComprising six Enterococcus avium, ﬁve Enterococcus casseliﬂavus, ﬁve Enterococcus
durans, four Enterococcus gallinarum and two Enterococcus hirae.
dComprising three Streptococcus acidominimus, 30 Streptococcus anginosus, 18 Strep-
tococcus constellatus, one Streptococcus defectivus, two Streptococcus gordonii, eight
Streptococcus intermedius, 35 Streptococcus mitis, three Streptococcus mutans, 38
Streptococcus oralis, 16 Streptococcus salivarius, 15 Streptococcus sanguis, three
Streptococcus vestibularis and one Streptococcus parasanguis.
eComprising 21 Streptococcus bovis, three Streptococcus dysgalactiae, three Streptococ-
cus equi, three Streptococcus equinus, two Streptococcus equisimilis, one Streptococcus
porcinus, one Streptococcus suis, one Lactococus spp., one Listeria monocytogenes, one
Micrococcus kristinae, two Micrococcus luteus and one Aerococcus viridans.
Brauers et al. Linezolid resistance in Germany 41
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 39–46
available for retesting in the reference laboratory.
MICs of linezolid ranged from 0.5 to 2 mg ⁄L for
all isolates, except one Staph. aureus (MIC 4 mg ⁄L)
(Table 2).
Comparative in-vitro activity of linezolid and
other antibiotics
The sample of representative isolates (n = 773)
sent to the reference laboratory for MIC testing
included 377 Staph. aureus, of which 258 were
methicillin-susceptible (MSSA) and 119 were
methicillin-resistant (MRSA), 91 Staph. epidermidis,
103 E. faecalis, 45 E. faecium, 33 Strep. pneumoniae,
35 Strep. pyogenes and 89 isolates of various other
species. Linezolid showed excellent in-vitro activ-
ity against the six species encountered most
frequently, with MIC50s and MIC90s of
1–2 mg ⁄L (Table 3). Linezolid-resistant isolates
(MIC > 4 mg ⁄L) were not detected. Resistance to
vancomycin or teicoplanin was also not detected,
except in one E. faecium isolate, which was
resistant to vancomycin (MIC ‡ 32 mg ⁄L) and
susceptible to teicoplanin. As expected, resistance
to other antibacterial agents was observed more
frequently among MRSA than among MSSA
isolates: erythromycin (77.3% vs. 17.8%), clinda-
mycin (68.1% vs. 2.7%), quinupristin–dalfopristin
(4.2% vs. 0.4%), doxycycline (14.3% vs. 6.6%),
levoﬂoxacin (75.6% vs. 5.4%) and rifampicin
(6.7% vs. 0%). All MSSA and MRSA isolates
were susceptible to vancomycin and teicoplanin.
Among the Staph. epidermidis isolates, 74.7%
were resistant to oxacillin (methicillin). Rates of
resistance for erythromycin, clindamycin, doxy-
cycline and levoﬂoxacin ranged between 20.9%
and 73.6%. In contrast, rates of resistance to
quinupristin–dalfopristin and rifampicin were
3.3% and 6.6%, respectively. Glycopeptide resist-
ance was not detected.
Among the E. faecalis and E. faecium isolates,
6.8% and 75.6%, respectively, were resistant to
ampicillin. High rates of resistance were observed
in both E. faecalis and E. faecium to levoﬂoxacin
(36.9% and 53.3%, respectively), erythromycin
(44.7% and 88.9%) and doxycycline (68.9% and
37.8%). Resistance to quinupristin–dalfopristin
was seen in 8.9% of E. faecium isolates. Resistance
to glycopeptides was not detected in E. faecalis.
One isolate of E. faecium was resistant to vanco-
mycin but susceptible to teicoplanin.
All isolates of Strep. pneumoniae and Strep.
pyogenes were susceptible to penicillin and levo-
ﬂoxacin. Rates of resistance for erythromycin,
clindamycin or doxycycline in these two species
were 15.2% and 14.3%, 6.1% and 2.9%, and
12.1% and 31.4%, respectively.
DISCUSSION
Resistance of Gram-positive bacteria to antimi-
crobial agents has increased in Germany. For
example, oxacillin resistance among Staph. aureus
blood isolates rose from 8% in 1983–1985 to 15%
in 2000–2001, and among blood isolates of CNS
from 41% in 1983–1985 to 68% in 2000–2001 [19].
Moreover, the percentage of invasive pneumo-
coccal isolates exhibiting reduced susceptibility to
Table 2. MICs of 69 isolates repor-
ted as ‘intermediate’ or ‘resistant’ to
linezolid following retesting by the
reference laboratorySpecies ⁄ organism
Number of
reporting
laboratories
Original susceptibility
testing method used by
the routine laboratory
(number of isolates)
MIC (mg ⁄L) of linezolid
(range) as determined by
the reference laboratory
Staphylococcus aureus (n = 24) 20 Agar diffusion NCCLS (7) 2–4a
Agar diffusion DIN (6)
Microdilution DIN (7)
Etest (4)
Enterococcus faecalis (n = 19) 17 Agar diffusion NCCLS (10) 1–2
Agar diffusion DIN (9)
Enterococcus faecium (n = 11) 10 Agar diffusion NCCLS (6) 0.5–2
Agar diffusion DIN (3)
Agar dilution DIN (1)
Etest (1)
Enterococcus spp. (n = 7) 7 Agar diffusion NCCLS (6) 2
Agar diffusion DIN (1)
Staphylococcus epidermidis (n = 3) 3 Agar diffusion DIN (3) 2
Streptococcus pyogenes (n = 3) 3 Agar diffusion NCCLS (1) 1
Agar diffusion DIN (1)
Etest (1)
Streptococcus pneumoniae (n = 2) 2 Etest (2) 1
aOne isolate with an MIC of 4 mg ⁄L.
NCCLS, National Committee for Clinical Laboratory Standards.
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Table 3. Comparison of in-vitro-activity of linezolid with other antibiotics against Gram-positive cocci (n = 773)a
Organism
Antibacterial
agent
MIC (mg ⁄L) Percentage of strains
£ 0.06 0.125 0.25 0.5 1 2 4 8 16 ‡ 32 MIC50 MIC90 Susceptible Intermediate Resistant
Methicillin-
susceptible
Staphylococcus
aureus
(n = 258)
Penicillin G 66 5 7 21 23 29 31 76b –c – 2 ‡ 8 27.5 NA 72.5
Erythromycin – – 3 45 143 16 5 1 1 44 1 ‡ 32 74.0 8.1 17.8
Clindamycin – – 239 9 1 1 1 0 0 7 £ 0.25 £ 0.25 96.5 0.8 2.7
Quinupristin–
dalfopristin
– – 231 21 – 3 1 0 0 0 £ 0.25 £ 0.25 98.4 1.2 0.4
Teicoplanin – – 165 77 12 4 0 0 0 0 £ 0.25 0.5 100 0 0
Vancomycin – – 10 193 49 6 0 0 0 0 0.5 1 100 0 0
Doxycycline – – 0 216 14 4 7 9 4 4 0.5 2 89.1 4.3 6.6
Levoﬂoxacin – 156 68 9 2 5 4 4 10b – £ 0.125 0.5 93.0 1.6 5.4
Rifampicin 246 7 3 2 0 0 0 0 – – £ 0.06 £ 0.06 100 0 0
Linezolid – – 0 1 62 186 9 0 0 0 2 2 96.5 3.5 0
Methicillin-
resistant
Staphylococcus
aureus
(n = 119)
Erythromycin – – 1 3 15 6 2 1 0 91 ‡ 32 ‡ 32 16.0 6.7 77.3
Clindamycin – – 34 0 1 2 1 0 1 80 ‡ 32 ‡ 32 29.4 2.5 68.1
Quinupristin–
dalfopristin
– – 52 50 10 2 1 3 1 0 0.5 1 94.1 1.7 4.2
Teicoplanin – – 59 28 21 10 1 0 0 0 0.5 1 100 0 0
Vancomycin – – 4 71 39 5 0 0 0 0 0.5 1 100 0 0
Doxycycline – – 0 86 11 2 3 0 7 10 0.5 16 81.5 4.2 14.3
Levoﬂoxacin – 4 5 2 0 1 17 32 58b – 8 ‡ 16 10.1 14.3 75.6
Rifampicin 100 5 0 0 2 4 2 6b – – £ 0.06 2 89.9 3.4 6.7
Linezolid – – 2 2 18 95 2 0 0 0 2 2 98.3 1.7 0
Staphylococcus
epidermidis
(n = 91)
Penicillin 10 1 3 8 4 6 8 51b – – ‡ 8 ‡ 8 12.1 NA 87.9
Oxacillin 11 4 1 3 4 6 9 53b – – ‡ 8 ‡ 8 25.3 NA 74.7
Erythromycin – – 4 7 9 2 2 0 2 65 ‡ 32 ‡ 32 22.0 4.4 73.6
Clindamycin – – 41 1 0 1 0 2 1 45 16 ‡ 32 46.2 1.1 52.7
Quinupristin–
dalfopristin
– – 81 4 1 2 2 1 0 0 £ 0.25 0.5 94.5 2.2 3.3
Teicoplanin – – 14 12 28 23 12 2 0 0 1 4 97.8 2.2 0
Vancomycin – – 2 16 64 6 3 0 0 0 1 1 100 0 0
Doxycycline – – 0 31 9 13 19 4 5 10 2 ‡ 32 44.0 35.1 20.9
Levoﬂoxacin – 16 3 5 0 14 20 17 16b – 4 ‡ 16 41.8 21.9 36.3
Rifampicin 78 2 0 2 2 1 1 5b – – £ 0.06 0.5 92.3 1.1 6.6
Linezolid – – 2 7 51 31 0 0 0 0 1 2 100 0 0
Enterococcus
faecalis
(n = 103)
Ampicillin – – 7 22 47 12 2 6 3 4 1 8 85.4 7.8 6.8
Erythromycin – – 3 0 10 16 28 6 2 38 4 ‡ 64 12.6 42.7 44.7
Teicoplanin – – 92 4 6 1 0 0 0 0 £ 0.25 0.5 100 0 0
Vancomycin – – 4 24 53 22 0 0 0 0 1 2 100 0 0
Doxycycline – – 0 19 9 0 4 2 12 57 ‡ 32 ‡ 32 27.2 3.9 68.9
Levoﬂoxacin – 6 3 13 41 2 0 2 36b – 1 ‡ 16 63.1 0 36.9
Linezolid – – 0 0 22 80 1 0 0 0 2 2 99.0 1.0 0
Enterococcus
faecium
(n = 45)
Ampicillin – – 0 2 3 0 5 1 1 33 ‡ 32 ‡ 32 11.1 13.3 75.6
Erythromycin – – 1 0 0 1 3 3 1 36 ‡ 32 ‡ 32 2.2 8.9 88.9
Quinupristin–
dalfopristin
– – 11 14 4 12 2 2 0 0 0.5 2 64.4 26.7 8.9
Teicoplanin – – 34 10 1 0 0 0 0 0 £ 0.25 0.5 100 0 0
Vancomycin – – 8 31 4 1 0 0 0 1 0.5 1 97.8 0 2.2
Doxycycline – – 0 24 3 1 0 0 0 17 0.5 32 60.0 2.2 37.8
Levoﬂoxacin – – 0 3 4 13 1 2 22b – 8 ‡ 16 44.4 2.2 53.3
Linezolid – – 0 0 16 27 2 0 0 0 2 2 95.6 4.4 0
Streptococcus
pneumoniae
(n = 33)
Penicillin G 33 0 0 0 0 0 0 0 – – £ 0.06 £ 0.06 100 NAc 0
Ampicillin – – 33 0 0 0 0 0 0 0 £ 0.25 £ 0.25 100 0 0
Erythromycin – – 26 1 0 0 1 2 0 3 £ 0.25 8 81.8 3.0 15.2
Clindamycin – – 31 0 0 0 0 0 0 2 £ 0.25 £ 0.25 93.9 0 6.1
Quinupristin–
dalfopristin
– – 12 15 6 0 0 0 0 0 0.5 1 100 0 0
Teicoplanin – – 32 0 1 0 0 0 0 0 £ 0.25 £ 0.25 100 0 0
Vancomycin – – 30 3 0 0 0 0 0 0 £ 0.25 £ 0.25 100 0 0
Doxycycline – – 1 20 6 1 1 0 1 3 0.5 16 81.8 6.1 12.1
Levoﬂoxacin – 0 0 9 22 1 1 0 0 – 1 1 97.0 3.0 0
Linezolid – – 1 12 20 0 0 0 0 0 1 1 100 0 0
Streptococcus
pyogenes
(n = 35)
Penicillin G 34 1 0 0 0 0 0 0 – – £ 0.06 £ 0.06 100 NA 0
Ampicillin – – 34 0 1 0 0 0 0 0 £ 0.25 £ 0.25 100 0 0
Erythromycin – – 27 0 0 1 2 3 0 0 £ 0.25 8 77.1 8.6 14.3
Clindamycin – – 34 0 0 0 0 0 0 1 £ 0.25 £ 0.25 97.1 0 2.9
Quinupristin–
dalfopristin
– – 32 2 0 0 1 0 0 0 £ 0.25 £ 0.25 97.1 0 2.9
Teicoplanin – – 35 0 0 0 0 0 0 0 £ 0.25 £ 0.25 100 0 0
Vancomycin – – 33 2 0 0 0 0 0 0 £ 0.25 £ 0.25 100 0 0
Doxycycline – – 0 18 6 0 0 0 4 7 0.5 ‡ 32 68.6 0 31.4
Levoﬂoxacin – 0 2 30 3 0 0 0 0 – 0.5 0.5 100 0 0
Linezolid – – 0 8 27 0 0 0 0 0 1 1 100 0 0
NA, not applicable.
aData for 89 isolates of various other genera ⁄ species, including 30 Staphylococcus spp., seven Staphylococcus haemolyticus, three Staphylococcus hominis, 22 Enterococcus spp.,
16 Streptococcus spp. and 11 Streptococcus agalactiae, are not shown. Linezolid resistance was not detected among these isolates.
bNumber of isolates with MIC greater than or equal to the value indicated.
cNot tested.
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penicillin increased from 1.8% to 5.8% between
1992 and 2000, and the percentage exhibiting
erythromycin resistance increased from 3.0% to
15.3% [20]. Linezolid, the ﬁrst representative of
the oxazolidinones, was developed for the treat-
ment of infections caused by Gram-positive path-
ogens, including multiresistant organisms such as
MRSA, oxacillin (methicillin)-resistant CNS, peni-
cillin ⁄macrolide-resistant pneumococci and
vancomycin-resistant enterococci.
The results of this study demonstrated that the
prevalence of linezolid resistance was still very
low in Germany. Based on routine susceptibility
results, rates of linezolid resistance were < 3% in
seven predominant species. Furthermore, all
isolates reported as intermediately resistant or
resistant to linezolid that were available for
retesting in the reference laboratory were found
to be susceptible to linezolid, with the exception
of a single isolate of Staph. aureus, which showed
intermediate resistance.
The ten Staph. aureus isolates (six MSSA; four
MRSA) reported as resistant to linezolid came
from seven laboratories. All isolates had been
tested routinely with the disk diffusion method,
except for one isolate that was tested with the
VITEK 2 system. MIC tests in the reference
laboratory failed to conﬁrm resistance in any of
these isolates, all of which had linezolid MICs of 1
or 2 mg ⁄L. The reasons for the inconsistent results
are unknown, but it seems either that the suscep-
tibility tests were performed incorrectly or that
the results were misinterpreted.
Glycopeptide resistance was reported for nine
Staph. aureus islates. Four isolates from three
laboratories were reported as vancomycin-resist-
ant, and ﬁve isolates from ﬁve laboratories as
teicoplanin-resistant. In each case, disk diffusion
was used as the initial susceptibility testing
method. None of these isolates was available for
conﬁrmation of species identiﬁcation and resist-
ance, but it seems likely that these results were
incorrect, as the disk diffusion method is unreli-
able for the testing of glycopeptide susceptibility.
Susceptibility testing of glycopeptides with the
disk diffusion method is not recommended in the
German DIN guidelines [21]. It has been reported
that the NCCLS disk diffusion method, the Stokes
method and the British Society for Antimicrobial
Chemotherapy standardised disk susceptibility
testing method also fail to detect reduced glyco-
peptide susceptibility accurately in Staph. aureus
[22–24]. There is a need for routine laboratories to
increase their awareness of the signiﬁcance of
resistance to glycopeptides or other new drugs
such as linezolid in Staph. aureus.
The present study of a representative sample of
773 isolates found that linezolid was the only
antibacterial agent active against all the Gram-
positive organisms tested. The susceptibility
results compared favourably with those found
in studies conducted previously in Germany,
other European countries and the USA [25–33].
The number of isolates tested in these studies
ranged from 245 to 5598. Linezolid MICs for
Staph. aureus, Staph. epidermidis, E. faecalis and
E. faecium varied between £ 0.25 and 4 mg ⁄L, and
those for Strep. pneumoniae and Strep. pyogenes
varied between £ 0.007 and 4 mg ⁄L. MIC90 values
for Staph. aureus ranged from 1.5 to 4 mg ⁄L, for
Staph. epidermidis and other CNS from 0.5 to
4 mg ⁄L, for E. faecalis from 1 to 4 mg ⁄L, for
E. faecium from 0.75 to 2 mg ⁄L, for Strep. pneumo-
niae from 0.5 to 1 mg ⁄L, and for Strep. pyogenes
from 0.5 to 2 mg ⁄L.
Although rare, the emergence of resistance to
linezolid has been reported in patients receiving
prolonged therapy [34–36], and prudent use of
linezolid is therefore recommended to keep
resistance at a low level. If resistance to glyco-
peptides or linezolid is suspected on the basis of
routine testing, retesting is recommended, either
in the same laboratory with an alternative
method, or in a reference laboratory, or both.
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